Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jan 20, 2026

Avian Influenza Surveillance with FTA Cards: Field Methods, Biosafety, and Transportation Issues Solved
12:09

Avian Influenza Surveillance with FTA Cards: Field Methods, Biosafety, and Transportation Issues Solved

Published on: August 2, 2011

19.7K

[Waldenström macroglobulinaemia].

Cécile Tomowiak1, Stéphanie Poulain2, Céline Debiais3

  • 1CHU de Poitiers, service d'oncohématologie et thérapie cellulaire, 86021 Poitiers.

Presse Medicale (Paris, France : 1983)
|August 25, 2019
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nivolumab with or without vinblastine for first-line treatment of elderly patients with Hodgkin lymphoma and coexisting medical conditions: the Niviniho phase II Lysa study.

Haematologica·2026
Same author

Outcomes and salvage strategies for large B-cell lymphoma progressing after second-line CAR T-cell therapy: A DESCAR-T study from the LYSA group.

HemaSphere·2026
Same author

Factors influencing front line treatment of chronic lymphocytic leukemia: A French real-world study.

Cancer·2026
Same author

BRAF inhibitor plus rituximab in classical hairy cell leukaemia: A retrospective multicentre real-life study.

British journal of haematology·2026
Same author

Anti-CD19 CAR T-cell therapy in relapsed/refractory T-cell/histiocyte-rich large B-cell lymphoma: insights from the French DESCAR-T registry, a LYSA study.

Haematologica·2026
Same author

CD3xCD20 bispecific antibodies in transformed Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.

HemaSphere·2026

Waldenstrom macroglobulinemia (WM) is a rare lymphoma diagnosed around age 70, often in frail patients. Targeted therapies like ibrutinib show promise for symptom management and maintenance in these individuals.

Area of Science:

  • Hematology
  • Oncology
  • Rare Diseases

Background:

  • Waldenstrom macroglobulinemia (WM) is a rare lymphoproliferative disorder.
  • Characterized by monoclonal IgM production and lymphoplasmacytic infiltration.
  • Typically affects an older, often frail, patient population with median age of 70.

Purpose of the Study:

  • To review the diagnostic and therapeutic landscape of WM.
  • To highlight the role of molecular markers in diagnosis.
  • To discuss current and emerging treatment strategies, particularly for frail patients.

Main Methods:

  • Literature review of WM diagnosis and treatment.
  • Focus on molecular diagnostics, including MYD88.
  • Analysis of first-line (DRC) and targeted therapy (ibrutinib) outcomes.

Related Experiment Videos

Last Updated: Jan 20, 2026

Avian Influenza Surveillance with FTA Cards: Field Methods, Biosafety, and Transportation Issues Solved
12:09

Avian Influenza Surveillance with FTA Cards: Field Methods, Biosafety, and Transportation Issues Solved

Published on: August 2, 2011

19.7K

Main Results:

  • WM presents with heterogeneous clinical features.
  • MYD88 mutation is a key molecular diagnostic marker.
  • Targeted therapies, such as ibrutinib, demonstrate efficacy and maintenance effects in frail patients.

Conclusions:

  • WM requires treatment only for symptomatic cases.
  • DRC remains a standard first-line therapy.
  • Ibrutinib offers a valuable option for frail patients, potentially improving outcomes and providing maintenance therapy.